JP2020522555A - 組み合わせ療法 - Google Patents

組み合わせ療法 Download PDF

Info

Publication number
JP2020522555A
JP2020522555A JP2019567709A JP2019567709A JP2020522555A JP 2020522555 A JP2020522555 A JP 2020522555A JP 2019567709 A JP2019567709 A JP 2019567709A JP 2019567709 A JP2019567709 A JP 2019567709A JP 2020522555 A JP2020522555 A JP 2020522555A
Authority
JP
Japan
Prior art keywords
antibody
antigen
icos
binding portion
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019567709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522555A5 (enExample
Inventor
ビー，メイシア
ビー． ホプソン，クリストファー
ビー． ホプソン，クリストファー
エー． メイズ，パトリック
エー． メイズ，パトリック
ヤダヴィリ，サプナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2020522555A publication Critical patent/JP2020522555A/ja
Publication of JP2020522555A5 publication Critical patent/JP2020522555A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019567709A 2017-06-09 2018-06-08 組み合わせ療法 Pending JP2020522555A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762517309P 2017-06-09 2017-06-09
US62/517,309 2017-06-09
US201862666278P 2018-05-03 2018-05-03
US62/666,278 2018-05-03
PCT/IB2018/054167 WO2018225033A1 (en) 2017-06-09 2018-06-08 Combination therapy

Publications (2)

Publication Number Publication Date
JP2020522555A true JP2020522555A (ja) 2020-07-30
JP2020522555A5 JP2020522555A5 (enExample) 2021-07-26

Family

ID=62873504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019567709A Pending JP2020522555A (ja) 2017-06-09 2018-06-08 組み合わせ療法

Country Status (6)

Country Link
EP (1) EP3634483A1 (enExample)
JP (1) JP2020522555A (enExample)
CN (1) CN110869049A (enExample)
BR (1) BR112019025325A2 (enExample)
CA (1) CA3066048A1 (enExample)
WO (1) WO2018225033A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3032897A1 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
WO2021209357A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
CN115461362A (zh) * 2020-04-14 2022-12-09 葛兰素史密斯克莱知识产权发展有限公司 基于ICOS抗体和PD-L1抗体TGF-β受体融合蛋白的癌症组合疗法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160215059A1 (en) * 2015-01-28 2016-07-28 Glaxosmithkline Intellectual Property Development Limited Icos binding proteins

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP2703011A3 (en) 2007-05-07 2014-03-26 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
JP5794917B2 (ja) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ Ｐｄ−１特異抗体およびその使用
CA2736829C (en) 2008-09-12 2018-02-27 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CN104826106B (zh) * 2009-09-30 2019-01-11 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
NO2504364T3 (enExample) 2009-11-24 2018-01-06
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
CN101898945B (zh) 2010-07-27 2013-05-08 大连理工大学 盐析萃取发酵液中丙酮和丁醇的方法
MX373443B (es) 2011-03-31 2020-05-20 Inst Nat Sante Rech Med Anticuerpos dirigidos contra icos y usos de los mismos.
EP2739358B1 (en) 2011-08-01 2018-11-28 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
EP2744830A4 (en) * 2012-06-21 2015-06-17 Compugen Ltd LSR ANTIBODIES AND USES THEREOF FOR THE TREATMENT OF CANCER
EP2892928B1 (en) 2012-09-03 2018-05-30 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies directed against icos for treating graft-versus-host disease
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
EP3030322A2 (en) * 2013-08-05 2016-06-15 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
EP3331919A1 (en) * 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160215059A1 (en) * 2015-01-28 2016-07-28 Glaxosmithkline Intellectual Property Development Limited Icos binding proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOL RES., vol. Vol. 4, Issue 11_Supplement, JPN6022025582, 2016, pages 22, ISSN: 0004977253 *

Also Published As

Publication number Publication date
EP3634483A1 (en) 2020-04-15
CA3066048A1 (en) 2018-12-13
CN110869049A (zh) 2020-03-06
WO2018225033A1 (en) 2018-12-13
BR112019025325A2 (pt) 2020-06-23

Similar Documents

Publication Publication Date Title
US12624106B2 (en) Combination of LILRB1/2 pathway inhibitors and PD-1 pathway inhibitors
JP6533270B2 (ja) がんを処置するための抗ｋｉｒ抗体と抗ｐｄ−１抗体との組み合わせ
JP7809062B2 (ja) 療法において使用するための抗体
KR20220032642A (ko) 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
JP7383620B2 (ja) 養子細胞療法およびチェックポイント阻害剤を使用する併用療法
CN111094982A (zh) 用于治疗和诊断癌症的tim-3拮抗剂
CN110869049A (zh) 组合疗法
US20240327544A1 (en) Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
US20200181275A1 (en) Combination therapy with icos agonist and ox40 agonist to treat cancer
EP4136105A1 (en) Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
US20200190194A1 (en) Combination therapy
JP2022505524A (ja) 投薬
JP2020522556A (ja) 癌を治療するためのｉｃｏｓアゴニストおよびｏｘ４０アゴニストでの組み合わせ療法
WO2024209072A1 (en) Multispecific binding agents against pd-l1 and cd137 for treating cancer
HK40110611A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
CN117957253A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
EA050156B1 (ru) Антитела для применения в терапии
HK40081753A (en) Antibodies for use in therapy
EA051733B1 (ru) Композиции, содержащие комбинацию анти-lag-3 антитела, ингибитора сигнального пути pd-1 и иммунотерапевтического средства

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230131